Physician profile
David Allen
NPI 1669693834
$352,306.14
in general payments reported to CMS, 2019-2025
21 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $15K · 2021: $50K · 2022: $67K · 2023: $51K · 2024: $58K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $164K · Consulting Fee: $10K · Travel and Lodging: $10K · Food and Beverage: $8,175 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,106.50 |
| Consulting Fee | $10,167.00 |
| Travel and Lodging | $10,000.50 |
| Food and Beverage | $8,175.21 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $95,960.05 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91,602.51 | 2020-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $77,543.16 | 2021-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $28,590.82 | 2019-2025 | |
| Lilly USA, LLC | $20,125.62 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10,628.93 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $8,961.38 | 2021-2024 | Optimizer |
| Novartis Pharmaceuticals Corporation | $8,250.89 | 2019-2021 | |
| Abbott Laboratories | $5,713.06 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Bridgebio Pharma, INC. | $2,365.91 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $1,520.89 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abiomed | $280.99 | 2019-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $241.25 | 2025 | Onpattro |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Boston Scientific Corporation | $177.02 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.66 | 2025 | Winrevair |
| Kestra Medical Technology Services, INC. | $35.50 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $27.54 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals Lp | $13.89 | 2022 | |
| Irhythm Technologies, INC. | $11.91 | 2019 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.